膜联蛋白A1和S100A16蛋白在脑胶质瘤中的表达及其意义  

Expression and significance of annexin A1 and S100A16 protein in human glioma

作　　者：廖秋林 赖续文 吴晓莉 韩丽芳 彭大云 庄洁娜 廖月媛 LIAO Qiu-lin;LAI Xu-wen;WU Xiao-li;HAN Li-fang;PENG Da-yun;ZHUANG Jie-na;LIAO Yue-yuan(Department of Pathology,Guangdong Clifford Hospital,Guangzhou,Guangdong 511495,China;不详)

机构地区：[1]广东祈福医院病理科,广东广州511495 [2]南部战区总医院病理科,广东广州510010

出　　处：《中华全科医学》2022年第10期1672-1674,1681,共4页Chinese Journal of General Practice

基　　金：广东省医学科研基金项目(A2019320)。

摘　　要：目的探讨膜联蛋白A1(ANXA1)和S100A16蛋白在脑胶质瘤组织中的表达水平及其意义。方法收集广东祈福医院和南部战区总医院在2015年1月—2020年12月确诊的160例胶质瘤病例以及20例胚胎发育不良性神经上皮肿瘤(DNT)病例,用免疫组化(IHC)方法检测ANXA1和S100A16蛋白的表达水平。结果ANXA1在胶质瘤组阳性率为80.6%(129/160),高于正常脑组织阳性率(7.5%,12/160)。S100A16在胶质瘤组阳性率为86.3%(138/160),高于正常脑组织组阳性率(10.0%,19/160)。ANXA1和S100A16在WHO分级Ⅰ~Ⅳ级胶质瘤中的阳性率差异无统计学意义。ANXA1在不包含WHOⅠ级的星形细胞来源肿瘤中的阳性率最高,达到95.0%(76/80),远比少突胶质细胞瘤中阳性率(42.9%,15/35)高。S100A16在不包含WHOⅠ级的星形细胞来源肿瘤中的阳性率(83.8%,67/80)与在少突胶质细胞瘤中阳性率(88.6%,31/35)比较差异无统计学意义。ANXA1在DNT组阳性率(100.0%,20/20)高于低级别胶质瘤组(78.8%,63/80)且差异有统计学意义。结论ANXA1可用于胶质瘤的辅助诊断标记,也可用于复杂型DNT与少突胶质细胞瘤的鉴别诊断,有一定的临床辅助诊断价值。S100A16的表达在胶质瘤中与正常脑组织之间差异有统计学意义,但不能作为辅助标记物用于DNT与低级别胶质瘤的鉴别诊断。Objective To investigate the expression level and significance of annexin A1(ANXA1)and S100A16 protein in glioma.Methods A total of 160 glioma cases and 20 dysembryoplastic neuroepithelial tumor(DNT)cases confirmed by Guangdong Clifford Hospital and General Hospital of Southern Theater Command from January 2015 to December 2020 were collected.The expression levels of ANXA1 and S100A16 proteins were detected by immunohistochemistry(IHC).Results The detectable rate of ANXA1 in glioma group was 80.6%(129/160),which was higher than that in normal brain tissue by 7.5%(12/160).The detectable rate of S100A16 in the glioma group was 86.3%(138/160),which was higher than that in the normal brain tissue group by 10.0%(19/160).No significant difference in the detectable rates of ANXA1 and S100A16 was found in the WHO gradeⅠ-Ⅳgliomas.The detectable rate of annexin A1 in astrocytoma without WHO gradeⅠwas the highest,reaching 95.0%(76/80),which was much higher than that in oligodendroglioma(42.9%,15/35).The detectable rate of S100A16 in astrocytoma without WHO gradeⅠ(83.8%,67/80)was not statistically significant compared with that in oligodendroglioma(88.6%,31/35).Significant difference in the detectable rate of ANXA1 was found between the DNT group(100.0%,20/20)and low-grade glioma group(78.8%,63/80).Conclusion ANXA1 can be used as an auxiliary diagnostic marker for glioma and for the differential diagnosis of complex DNT and oligodendroglioma.Statisical difference in the expression of S100A16 differed between glioma and normal brain tissue,but S100A16 cannot be used as an auxiliary marker in the differential diagnosis of DNT and low-grade glioma.

关 键 词：胶质瘤 胚胎发育不良性神经上皮肿瘤 膜联蛋白A1 S100A16 免疫组织化学 

分 类 号：R739.41[医药卫生—肿瘤]